Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro
Erik C. Gunther*,,
David J. Stone*,
Robert W. Gerwien,
Patricia Bento, and
Melvyn P. Heyes
CuraGen Corporation, 322 East Main Street, Branford, CT 06405
Accepted for publication June 11, 2003.
Received for publication April 30, 2003.
Abstract:
Assays of drug action typically evaluate biochemical activity.However, accurately matching therapeutic efficacy with biochemicalactivity is a challenge. High-content cellular assays seekto bridge this gap by capturing broad information about thecellular physiology of drug action. Here, we present a methodof predicting the general therapeutic classes into which variouspsychoactive drugs fall, based on high-content statistical categorization of gene expression profiles induced by thesedrugs. When we used the classification tree and random forestsupervised classification algorithms to analyze microarraydata, we derived general "efficacy profiles" of biomarker geneexpression that correlate with anti-depressant, antipsychoticand opioid drug action on primary human neurons in vitro. Theseprofiles were used as predictive models to classify naïvein vitro drug treatments with 83.3% (random forest) and 88.9%(classification tree) accuracy. Thus, the detailed informationcontained in genomic expression data is sufficient to matchthe physiological effect of a novel drug at the cellular levelwith its clinical relevance. This capacity to identify therapeuticefficacy on the basis of gene expression signatures in vitrohas potential utility in drug discovery and drug target validation.
Key Words: pharmacogenomics predictive efficacy drug screening
To whom correspondence should be addressed. E-mail: egunther{at}curagen.com.
* E.C.G. and D.J.S. contributed equally to this work.
Edited by Floyd E. Bloom, The Scripps Research Institute, LaJolla, CA
This paper was submitted directly (Track II) to the PNAS office.
Data mining in the Life Sciences with Random Forest: a walk in the park or lost in the jungle?.
W. G. Touw, J. R. Bayjanov, L. Overmars, L. Backus, J. Boekhorst, M. Wels, and S. A. F. T. van Hijum (2013)
Brief Bioinform
14, 315-326
|Abstract »|Full Text »|PDF »
Drug Discovery in Psychiatric Illness: Mining for Gold.
Successful anti-cancer drug targets able to pass FDA review demonstrate the identifiable signature distinct from the signatures of random genes and initially proposed targets.
A. L. Mayburd, I. Golovchikova, and J. L. Mulshine (2008)
Bioinformatics
24, 389-395
|Abstract »|Full Text »|PDF »
Discovering Antibiotic Efficacy Biomarkers: TOWARD MECHANISM-SPECIFIC HIGH CONTENT COMPOUND SCREENING.
C. Freiberg, N. Brunner, L. Macko, and H. P. Fischer (2006)
Mol. Cell. Proteomics
5, 2326-2335
|Abstract »|Full Text »|PDF »
Eigengene-based linear discriminant model for tumor classification using gene expression microarray data.
R. Shen, D. Ghosh, A. Chinnaiyan, and Z. Meng (2006)
Bioinformatics
22, 2635-2642
|Abstract »|Full Text »|PDF »
Integrated mechanistic and data-driven modelling for multivariate analysis of signalling pathways.
F. Hua, S. Hautaniemi, R. Yokoo, and D. A Lauffenburger (2006)
J R Soc Interface
3, 515-526
|Abstract »|Full Text »|PDF »
Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells.
Y. C. Lim, L. Li, Z. Desta, Q. Zhao, J. M. Rae, D. A. Flockhart, and T. C. Skaar (2006)
J. Pharmacol. Exp. Ther.
318, 503-512
|Abstract »|Full Text »|PDF »
Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins.
M. Mesri, G. Smithson, A. Ghatpande, A. Chapoval, S. Shenoy, F. Boldog, C. Hackett, C. E. Pena, C. Burgess, A. Bendele, et al. (2006)
Int. Immunol.
18, 473-484
|Abstract »|Full Text »|PDF »
Pooling samples within microarray studies: a comparative analysis of rat liver transcription response to prototypical toxicants.
R. A. Jolly, K. M. Goldstein, T. Wei, H. Gao, P. Chen, S. Huang, J.-M. Colet, T. P. Ryan, C. E. Thomas, and S. T. Estrem (2005)
Physiol Genomics
22, 346-355
|Abstract »|Full Text »|PDF »
nsSNPAnalyzer: identifying disease-associated nonsynonymous single nucleotide polymorphisms.
Classification of a large microarray data set: Algorithm comparison and analysis of drug signatures.
G. Natsoulis, L. El Ghaoui, G. R.G. Lanckriet, A. M. Tolley, F. Leroy, S. Dunlea, B. P. Eynon, C. I. Pearson, S. Tugendreich, and K. Jarnagin (2005)
Genome Res.
15, 724-736
|Abstract »|Full Text »|PDF »
Discovering the Mechanism of Action of Novel Antibacterial Agents through Transcriptional Profiling of Conditional Mutants.
C. Freiberg, H. P. Fischer, and N. A. Brunner (2005)
Antimicrob. Agents Chemother.
49, 749-759
|Abstract »|Full Text »|PDF »
Multidimensional Drug Profiling By Automated Microscopy.
Z. E. Perlman, M. D. Slack, Y. Feng, T. J. Mitchison, L. F. Wu, and S. J. Altschuler (2004)
Science
306, 1194-1198
|Abstract »|Full Text »|PDF »
Multiplex mRNA assay using electrophoretic tags for high-throughput gene expression analysis.
H. Tian, L. Cao, Y. Tan, S. Williams, L. Chen, T. Matray, A. Chenna, S. Moore, V. Hernandez, V. Xiao, et al. (2004)
Nucleic Acids Res.
32, e126
|Abstract »|Full Text »|PDF »
Reproducibility, Sources of Variability, Pooling, and Sample Size: Important Considerations for the Design of High-Density Oligonucleotide Array Experiments.
E.-S. Han, Y. Wu, R. McCarter, J. F. Nelson, A. Richardson, and S. G. Hilsenbeck (2004)
J Gerontol A Biol Sci Med Sci
59, B306-B315
|Abstract »|Full Text »|PDF »
Toxicogenomic Approach to Endocrine Disrupters: Identification of a Transcript Profile Characteristic of Chemicals with Estrogenic Activity.
J. M. Naciff and G. P. Daston (2004)
Toxicol Pathol
32, 59-70
|Abstract »|PDF »
Microarray Analysis in Drug Discovery: An Uplifting View of Depression.